Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States-Reference-Cited by-同舟云学术

Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States

Published:2022-09 Issue:9 Volume:28 Page:581.e1-581.e8
ISSN:2666-6367
Container-title:Transplantation and Cellular Therapy
language:en
Short-container-title:Transplantation and Cellular Therapy

Author:

Jacobson Caron A.,Locke Frederick L.^ORCID,Ma Long,Asubonteng Julius,Hu Zhen-Huan,Siddiqi Tanya,Ahmed Sairah,Ghobadi Armin,Miklos David Bernard,Lin Yi,Perales Miguel-Angel^ORCID,Lunning Matthew Alexander,Herr Megan M.,Hill Brian T.,Ganguly Siddhartha^ORCID,Dong Hua,Nikiforow Sarah,Hooper Michele,Kawashima Jun^ORCID,Xu Hairong,Pasquini Marcelo C.^ORCID

Publisher

Elsevier BV

Subject

Transplantation,Cell Biology,Hematology,Molecular Medicine,Immunology and Allergy

Reference19 articles.

1. Management of relapsed-refractory diffuse large B cell lymphoma;Raut;South Asian J Cancer,2014

2. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity;Sehn;Blood,2015

3. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study;Crump;Blood,2017

4. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma;Neelapu;N Engl J Med,2017

5. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial;Locke;Lancet Oncol,2019

Cited by 94 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CAR T-cells in very elderly (≥80 years) lymphoma patients: a DESCAR-T analysis;Leukemia & Lymphoma;2024-08-13

2. Approved CAR-T therapies have reproducible efficacy and safety in clinical practice;Human Vaccines & Immunotherapeutics;2024-08-05

3. Biomarkers of outcome in patients undergoing CD19 CAR‐T therapy for large B cell lymphoma;HemaSphere;2024-08

4. Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma;Blood;2024-07-18

5. Real-world outcomes with novel therapies in relapsed/refractory diffuse large B-cell lymphoma;Leukemia & Lymphoma;2024-07-16